|
|
I A Heijnen, M J van Vugt, N A Fanger, R F Graziano, T P de Wit, F M Hofhuis, P M Guyre, P J Capel, J S Verbeek, J G van de Winkel
J Clin Invest. 1996;
97(2):331
doi:10.1172/JCI118420
Abstract |
Full text
| PDF

B
esides their phagocytic effector functions, myeloid cells have an essential role as accessory cells in the induction of optimal humoral immune responses by presenting captured antigens and activating lymphocytes. Antigen presentation by human monocytes was recently found to be enhanced in vitro through the high-affinity Fc receptor for IgG (Fc gamma RI; CD64), which is exclusively present on myeloid cells. To evaluate a comparable role of Fc gamma RI in antigen presentation in vivo, we generated human Fc gamma RI transgenic mice. Under control of its endogenous promoter, human Fc gamma RI was selectively expressed on murine myeloid cells at physiological expression levels. As in humans, expression was properly regulated by the cytokines IFN-gamma, G-CSF, IL-4, and IL-10, and was up-regulated during inflammation. The human receptor expressed by murine macrophages bound monomeric human IgG and mediated particle phagocytosis and IgG complex internalization. To evaluate whether specific targeting of antigens to Fc gamma RI can induce enhanced antibody responses, mice were immunized with an anti-human Fc gamma RI antibody containing antigenic determinants. Transgenic mice produced antigen-specific antibody responses with high IgG1 titers and substantial IgG2a and IgG2b responses. These data demonstrate that human Fc gamma RI on myeloid cells is highly active in mediating enhanced antigen presentation in vivo, and show that anti-Fc gamma RI mAbs are promising vaccine adjuvants.
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal.
Not all publishers participate in CrossRef, so this information is not comprehensive.
Additionally, data may not reflect the most current citations to this article,
and the data may differ from citation information available from other sources
(for example, Google Scholar, Web of Science, and Scopus).
Total citations by year
in CrossRef
Citations to this article
in CrossRef
(45)
| Title and authors |
Publication |
Year |
Mechanism of action of therapeutic monoclonal antibodies: promises and pitfalls of in vitro and in vivo assays
Josée Golay, Martino Introna
|
Archives of Biochemistry and Biophysics
|
2012 |
Cytokine-induced immune complex binding to the high-affinity IgG receptor, Fc RI, in the presence of monomeric IgG
C. E. van der Poel, R. A. Karssemeijer, P. Boross, J. A. van der Linden, M. Blokland, J. G. J. van de Winkel, J. H. W. Leusen
|
Blood
|
2010 |
Activating and inhibitory Fcγ receptors in immunotherapy: being the actor or being the target
Riad Abès, Charles-Antoine Dutertre, Lauren Agnelli, Jean-Luc Teillaud
|
Expert Rev Clin Immunol
|
2009 |
Fc receptor-targeted mucosal vaccination as a novel strategy for the generation of enhanced immunity against mucosal and non-mucosal pathogens
Edmund J. Gosselin, Constantine Bitsaktsis, Ying Li, Bibiana V. Iglesias
|
Arch. Immunol. Ther. Exp.
|
2009 |
Neutrophils in antibody-based immunotherapy of cancer
Marjolein van Egmond
|
Expert Opin. Biol. Ther.
|
2008 |
Surfactant protein D/anti-Fc receptor bifunctional proteins as a tool to enhance host defence
Esther CW Breij, Joseph J Batenburg
|
Expert Opin. Biol. Ther.
|
2008 |
Targeting allergen to Fc gammaRI: a strategy to treat allergic disease?
Kathryn E Hulse, Judith A Woodfolk
|
Current Opinion in Allergy and Clinical Immunology
|
2008 |
Prostaglandin E2 modulates dendritic cell function during chlamydial genital infection.
Wei Liu, Kathleen Ann Kelly
|
Immunology
|
2008 |
Malaria vaccines: immunity, models and monoclonal antibodies
Lars Hviid, Lea Barfod
|
Trends in Parasitology
|
2008 |
A novel Fcγ receptor ligand augments humoral responses by targeting antigen to Fcγ receptors
Mark A. Jensen, Barry G. W. Arnason, David M. White
|
Eur. J. Immunol.
|
2007 |
|